KraneShares MSCI All China Health Care Index ETF (KURE) is a China-focused ETF. As of October 28, 2026, ETF Copilot scores KURE 3.3 out of 10 — highest on Value (7.9), lowest on Return (0.4). It trades at 22.0 times earnings, against its own median of 24.0. Its ten largest holdings are 54% of the fund.
What stands out in KURE's data
Chinese healthcare companies, from drugmakers to medical-device firms.
Earns more on its capital than most China-sector peers — a sign of real pricing power.
Return on invested capital of 26.8% is roughly double the 13.6% category median, and ahead of its own 20.5% historical norm. Holdings: 42 stocks.
A sector bet on China's healthcare industry, built for portfolios that want targeted growth exposure.
Why did KURE move this week? It fell 2.3% in the week to October 28, 2026 — Innovent Biologics and Beone Medicines drove it
KURE fell 2.3% in the week to October 28, 2026. The holdings that moved it most were Innovent Biologics (−8.8%), Beone Medicines (−4.9%) and Wuxi Biologics (−6.2%); Genscript Biotech (+7.0%) pushed the other way.
How is KURE rated? ETF Copilot scores KraneShares MSCI All China Health Care Index ETF (KURE) 3.3 out of 10
As of October 28, 2026, ETF Copilot scores KraneShares MSCI All China Health Care Index ETF (KURE) 3.3 out of 10 overall.
ETF Copilot scores (0–10 scale, higher is better):
- Overall: 3.3 / 10
- Growth: 2.6 / 10
- Value: 7.9 / 10
- Risk: 0.5 / 10
- Quality: 7.1 / 10
- Return: 0.4 / 10
KURE is ranked #9 of 10 in ETF Copilot's Rising Stars list.
Is KURE expensive right now? It trades at 22.0 times earnings, against its own median of 24.0
As of October 28, 2026, KURE is cheaper than 75% of its own last 9 years.
Trailing 12 months, built from KURE's holdings. How we calculate this →
What's inside KURE?
What's inside KURE: Size (Large 31%, Mid 63%, Small 7%); Geography (International 99%, US 1%).
What are KURE's top holdings? The ten largest are 54% of the fund
Beone Medicines, Innovent Biologics, Wuxi Biologics, Wuxi Apptec, Shenzhen Mindray Bio-Medic-A, Jiangsu Hengrui Medicine, Akeso, Sino Biopharmaceutical and Cspc Pharmaceutical are KURE's largest holdings, in that order.
More concentrated than 55% of China ETFs.
Half of KURE's weight sits in its 9 largest positions, and once those weights are taken into account it behaves like 24 equally weighted holdings.
What is KURE's expense ratio? 0.79% a year
As of October 28, 2026, KURE charges 0.79% a year, yields 4.02% and holds $107M in assets across 42 positions.
| Measure | KURE |
|---|---|
| Expense ratio | 0.79% |
| Dividend yield | 4.02% |
| Assets under management | $107M |
| Holdings | 42 |
Expense ratio, dividend yield and assets under management are reported by the fund and refreshed daily. Every other figure on this page is computed by ETF Copilot.
Cite this
ETF Copilot, “KraneShares MSCI All China Health Care Index ETF (KURE) scores and holdings analysis”, as of October 28, 2026.
https://etf-copilot.com/etf/kure
ETF Copilot Pro unlocks KURE's price and what each holding weighs.
Try Pro free →